Aim To evaluate whether recent low adherence to metformin monotherapy is associated with hypoglycaemia after addition of a sulfonylurea.
Introduction
Anti-hyperglycaemic medications are an important part of diabetes management, but adherence to these medications is often suboptimal. Overall, anti-hyperglycaemic medication adherence among people with Type 2 diabetes mellitus is estimated to be 36-85%, and up to a third of individuals who are prescribed metformin discontinue the drug within 1 year [1, 2] . Many factors affect medication adherence, including cost, side effects, number of concurrent medications, beliefs about medications, and relationship with provider [2] [3] [4] . The level of adherence to anti-hyperglycaemic medications can impact both short-term diabetes treatment goals, including HbA 1c , and long-term clinical outcomes such as cardiovascular, cerebrovascular and renal events, among others [5] [6] [7] [8] [9] .
While it is ideal to address any problems with adherence prior to intensifying treatment, in clinical practice, providers often decide to intensify therapy based on physiological or laboratory measurements regardless of the level of medication adherence because of challenges or barriers to ascertaining past medication use objectively. When an individual with Type 2 diabetes mellitus on metformin has elevated HbA 1c levels attributable to nonadherence, the provider may decide to intensify antihyperglycaemic therapy by adding another agent such as a Correspondence to: Jea Young Min. E-mail: jea.y.min@vanderbilt.edu sulfonylurea to the current regimen; however, if the individual decides to take the medications more regularly from that point forward, he or she could be exposed to a more intensive regimen than was necessary, increasing the risk of hypoglycaemic events. We conducted a retrospective cohort study to evaluate whether recent low adherence to metformin monotherapy was a risk factor for early hypoglycaemia events following intensification of therapy with a sulfonylurea.
Participants and methods

Study design and data sources
We used national US Veterans Health Administration (VHA) databases which include administrative, clinical and laboratory data, linked through identifiers designed for research, to construct a retrospective cohort of veterans with Type 2 diabetes. Sources of data included: dispensed medication information (fill date, days' supply, number of pills); demographic data; diagnostic and procedure information from inpatient and outpatient encounters, coded using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) system [10] ; and laboratory test results and vital signs (blood pressure, height, weight) from standard clinical sources. For participants enrolled in Medicare or Medicaid, additional data were obtained from the US Centres for Medicare and Medicaid Services through an inter-agency exchange agreement [11] . Dates of death were obtained from the National Death Index prior to 2011, and VHA vital status files were used as a supplement to identify subsequent dates of death from 2011 to 2012. The institutional review board of the VHA Tennessee Valley Healthcare System approved this study.
Study population
The study population included veterans aged ≥18 years who received regular care at the VHA. Regular care was defined as having at least one inpatient or outpatient encounter or a prescription fill every 360 days in the prior 2 years. We identified new users of metformin from October 2001 to September 2011, with at least 365 days of baseline data and no anti-hyperglycaemic drug fill in the past 180 days. Participants were excluded if they did not refill metformin at least once during the initial 12 months of therapy. This criterion was added to exclude participants who did not refill as a result of gastrointestinal intolerance or other side effects to metformin. Metformin initiators who refilled their medication at least once became eligible for the intensification cohort when they first filled a sulfonylurea (glibenclamide, glipizide or glimepiride) prescription (Fig. S1 ). The time on metformin monotherapy was required to be at least 12 months to assess adherence. Participants were not required to have a metformin supply on hand at the time of intensification with sulfonylureas.
Participants receiving hospice care or dialysis at the time of intensification (Table S1) , and those with missing birth date or gender were excluded.
Exposures
The exposure of interest was recent metformin adherence at therapy intensification with a sulfonylurea. Prescription refill records were used to define adherence as a continuous variable representing the proportion of metformin days covered during the 6-month period prior to intensification (Fig. S1 ) [12] .
Based on previous studies, we dichotomized the comparison groups in our study population for the primary analysis into participants with low (<80%) and high (≥80%) metformin adherence at intensification [12, 13] . Follow-up began after intensification and continued for up to a year until study outcome, regimen change (filled a third antihyperglycaemic agent), loss to follow-up (181 days without VHA contact), death, or end of study (30 September 2012; Fig. S1 ).
Primary outcome: hypoglycaemia
The primary outcome was time to first hypoglycaemia within 1 year of intensification with a sulfonylurea. Recurrent events were not considered in the study. Hypoglycaemia was a composite of three event types: hospitalization for hypoglycaemia, emergency department visit because of hypoglycaemia, or an outpatient blood glucose measurement <3. • Providers often intensify anti-hyperglycaemic treatment for people with Type 2 diabetes mellitus based on laboratory measurements without accurate assessment of adherence, potentially exposing those with low adherence to a more intensive regimen than necessary.
• This retrospective cohort study, which included incident users of metformin intensifying treatment, found that recent low adherence to metformin monotherapy was not associated with hypoglycaemia in the year following intensification with a sulfonylurea.
• While it is important for providers to evaluate medication adherence, this study does not suggest that intensifying treatment in the presence of recent nonadherence is associated with a higher risk of hypoglycaemia.
only). [14] .
Secondary outcome
For the secondary analysis, we described median HbA 1c measurements in participants with low vs high adherence at baseline and 12 months after intensification, among those alive during the study period. We also compared the adjusted proportion (by baseline HbA 1c ) of participants with decrease in HbA 1c of >11 mmol/mol (1.0%) during the study period.
Covariates
Baseline covariate information was collected from up to 730 days prior to intensification (t 1 ). Covariates included: age (continuous); sex; race (white, black, other); year of metformin initiation; indicators of healthcare use (hospitalization during past year, nursing home residence, number of outpatient visits, Medicare or Medicaid utilization); physiological variables (BMI, systolic and diastolic blood pressure, HbA 1c level, LDL cholesterol level, proteinuria, serum creatinine level); estimated GFR, calculated using the Chronic Kidney Disease Epidemiology Collaboration formula [15] ; duration of metformin monotherapy (proxy for diabetes duration); selected medications; smoking; and selected comorbidities (Table S2 for further details). We also considered the type (glipizide, glibenclamide or glimepiride) and dose of sulfonylurea added. One defined daily dose was defined as 10 mg for glipizide, 10 mg for glibenclamide, and 2 mg for glimepiride according to the WHO [16] .
Multiple imputation was conducted (30 imputations) for missing covariates using an iterative Markov chain Monte Carlo method for both the construction of propensity scores and for the final outcome model in the primary analysis [17] . For continuous variables, restricted cubic splines were included in the final outcome model to account for nonlinearity [18] .
Data cleaning and quality control
For blood glucose values obtained in the outpatient setting, we excluded non-numeric values (such as 'high' or 'low') and converted non-absolute values to absolute values so that a blood glucose value >22.2 mmol/l would be coded as 22.2, and a blood glucose value <3.9 mmol/l would be coded as 3.9. If a participant had hypoglycaemia based on the outpatient blood glucose or emergency room visit definition, which led to a hospitalization within 48 hours, the event was counted as a single event attributed to the hospitalization.
Similarly, if a participant had hypoglycaemia based on an outpatient blood glucose which led to an emergency visit, the event was attributed to the emergency room visit.
Statistical analyses
The primary analysis evaluated the time to first hypoglycaemia event among participants with low adherence vs high adherence, using a Cox proportional hazards model adjusting for baseline covariates. The study population was weighted using propensity-score-matching weights [19] . The propensity scores modelled the probability of low adherence based on covariate information and service network of care, and the weights scaled the high and low adherence groups to resemble a 1:1 matched cohort. Results of the propensity-score models are presented in separate figures and tables ( Fig. S2 and Table S3 ). For the secondary analysis, we described the median HbA 1c at baseline and at 12 months after intensification among participants who survived and had a baseline HbA 1c measurement. Using a logistic regression model adjusting for baseline HbA 1c , we estimated the adjusted proportion of participants with a decrease in HbA 1c of >11 mmol/mol (1.0%) for the low and high adherence groups.
Subgroup and sensitivity analyses
We examined whether the association between low adherence and risk of hypoglycaemia differed by two potential effect modifiers: sulfonylurea type and dose. Subgroup analyses were conducted for participants who intensified treatment with glibenclamide vs glipizide or glimepiride, and for those who added a high dose of a sulfonylurea (≥1 defined daily dose) vs a low dose of a sulfonylurea (<1 defined daily dose).
For the sensitivity analysis, we modelled medication adherence as a continuous variable using restricted cubic splines in a Cox proportional hazard model adjusting for baseline covariates [18] . This analysis was performed to examine whether there was a non-linear association between adherence and the hypoglycaemia outcome, or if there was a tipping point at which the risk of hypoglycaemia increased.
Results
Study population
We identified 187 267 participants who initiated metformin monotherapy, 49 424 of whom intensified therapy with a sulfonylurea after being on metformin monotherapy for at least 1 year and did not meet other exclusion criteria (Fig. 1) . Participants in the intensification cohort were 96% men and 84% white, and the median [interquartile range (IQR)] age was 63 (57-72) years. The median (IQR) metformin adherence in the 6 months prior to intensification was 87 (50-100)% (Fig. S3 ): in the low adherence group it was 47 (16-63)% and in the high adherence group it was 100 (94-100)%. A total of 21 419 participants (43%) had low adherence. Prior to propensity-score weighting, participants in the low adherence group on average were slightly younger, were less often white, had a shorter duration of metformin monotherapy and higher HbA 1c at intensification, and were on fewer outpatient medications ( Table 1 ). The median (IQR) total number of outpatient laboratory blood glucose measurements during the 1-year follow-up period was 4 (2-6) in both the low adherence and high adherence groups.
Primary outcome: hypoglycaemia
Of the 49 424 study participants, 1100 (2.2%) had a hypoglycaemia event during the first year of intensification (10 hospitalizations, 143 emergency department visits and 947 outpatient events); 10.7% were censored for death, end of study, or were no longer in contact with the VHA. Among the low adherence group, 456 (2.1)% had a hypoglycaemia event (three hospitalizations, 62 emergency department visits, and 391 outpatient events), and among the high adherence group, 644 (2.3%) had a hypoglycaemia event (seven hospitalizations, 81 emergency department events and 556 outpatient events). The rates of hypoglycaemia per 1000 person-years were 23.1 (95% CI 21.1, 25.4) and 24.5 (95% CI 22.7, 26.4) for the low and high adherence group, respectively. After propensity-score weighting and further adjusting for baseline covariates in the Cox model, the risk of hypoglycaemia among participants in the low adherence group was similar to that among those in the high adherence group (adjusted hazard ratio 0.95, 95% CI 0.84-1.08; Table 2 ).
Subgroup and sensitivity and analyses
The subgroup analyses results were consistent with the main findings ( Table 2) . When adherence was modelled as a continuous variable using restricted cubic splines, there was no evidence of a linear or non-linear association between levels of adherence and risk of hypoglycaemia (Fig. 2) .
Relationship between adherence and change in HbA 1c
The median (IQR) baseline HbA 1c for the low and high adherence groups was 58 (51-70) mmol/mol [7.5 (6.8, 
Discussion
In the present study of veterans with Type 2 diabetes, we found no evidence that recent low metformin monotherapy adherence was associated with an increased risk of 18  18  18  18  2004  20  20  20  20  2005  21  22  22  22  2006  22  21  21  22  2007  16  14  15  15 ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; DDD, defined daily dose; IQR, interquartile range; VHA, Veterans Health Administration. *Standardized differences are the absolute difference in means or percent divided by an evenly weighted pooled standard deviation, or the difference between groups in number of standard deviations. † Days on metformin monotherapy is an approximation of the duration of diabetes since participants were free of all hypoglycaemic medications for 180 days prior to starting metformin.
developing early hypoglycaemia after intensifying treatment with a sulfonylurea. A smaller proportion of participants with low adherence had a >11 mmol/mol (1.0%) decrease in HbA 1c compared to those in the high adherence group when accounting for baseline HbA 1c . The risk of hypoglycaemia appeared to be similar across different levels of recent adherence to metformin when we modelled adherence as a continuous variable in our sensitivity analysis. We had limited power to evaluate the association in those with very low adherence (<30%) as indicated by the wide confidence intervals.
While it is important to evaluate medication adherence, results of the present study do not suggest that intensifying treatment in the presence of recent non-adherence is associated with higher risk of hypoglycaemia. Improvements in HbA 1c levels were seen in participants with low and high adherence. In a study of hypertension, Rose et al. [20] found that anti-hypertensive treatment intensification improved blood pressure control similarly among participants with different levels of adherence. The authors argue that, while addressing adherence is important, it may not be a necessary step prior to intensifying therapy for hypertension. Similarly, for anti-hyperglycaemic drug therapy among people with Type 2 diabetes mellitus, clinicians may intensify treatment based on HbA 1c or glucose measurements before addressing adherence issues, and the present study suggests this may lead to favourable changes in glycaemic control without a greater risk of hypoglycaemia.
Two previous studies have explored the relationship between anti-hyperglycaemic medication adherence and the outcome of hypoglycaemia, although the specific research questions differed. Quilliam et al. [21] examined whether the risk of hypoglycaemia differed depending on the adherence and change in regimen during the first 6 months of metformin, sulfonylurea, or thiazolidinedione therapy. The overall rates of hypoglycaemia in their study were similar to our observed event rates (0.9-2.6%). Those authors found that the hazard of hypoglycaemia was higher among participants switching to combination therapy compared to metformin users who were highly adherent; however, they did not specifically evaluate how the observed adherence could relate to hypoglycaemia after switching to combination therapy. Hsu et al. [22] used a cross-sectional design to examine the relationship between self-reported adherence and adverse safety events, including hypoglycaemia. They found that lower adherence by self-report was associated with more adverse safety outcomes by self-report (prevalence ratio 1.21, 95% CI 1.04-1.41), but the specific results for hypoglycaemia were not reported, and the temporal relationship could not be established because of the crosssectional study design.
The national VHA population is an ideal population in which to study medication adherence and evaluate how it relates to clinical outcomes such as hypoglycaemia, because most people receive their medications through the VHA pharmacy at lower costs and have detailed records of prescription medication fills and healthcare encounters. As in any observational study, unmeasured confounding could have affected our results, but we were able to use advanced survival methods to balance many potential confounders in the comparison groups by applying propensity-score weighting and covariate adjustment.
A limitation of the present study is that we did not examine post-intensification adherence to sulfonylureas. Because the VHA often dispenses a 90-day supply of medications to promote high adherence, the ability to detect meaningful changes in adherence after intensification would have required a longer follow-up. Another limitation is that hypoglycaemia is often not captured in medical records because many people do not present to the hospital or obtain glucose measurements even when they have a moderate to severe event. In addition, veterans may not receive all care at VHA facilities, so events may be missed; however, the present data were supplemented by Medicare and Medicaid encounter information, which should have reduced missed events. We also lacked information on certain confounders including participant education or provider quality of care. Finally, the cohort included mostly white men, typical of a US veteran population [23], which should be considered when generalizing the study results to other populations.
In conclusion, we found no evidence that low metformin monotherapy adherence was a risk factor for early hypoglycaemia events after intensification with a sulfonylurea. In addition, the risk of hypoglycaemia did not appear to change across different levels of adherence. 
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